OPUS GENETICS INC(IRD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IRD OPUS GENETICS INC

Closed Good Friday 04-17 16:00:00 EDT

0.7599

+0.0248

+3.37%

盘后0.7599

+0.00000.00%

19:38 EDT

High0.8100	Low0.7290	Vol52.77K
Open0.7290	D1 Closing0.7351	Amplitude11.02%
Mkt Cap34.56M	Tradable Cap27.45M	Total Shares45.48M
T/O39.71K	T/O Rate0.15%	Tradable Shares36.13M
P/B5.14	ROE-152.46%	EPS-2.15
52wk High2.18	52wk Low0.6500	P/E-0.35
Dividend0.00	Div.Yield0.00	ROA-46.90%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"IRD","market":"US","secType":"STK","nameCN":"OPUS GENETICS INC","latestPrice":0.7599,"timestamp":1744920000000,"preClose":0.7351,"halted":0,"volume":52772,"hourTrading":{"tag":"盘后","latestPrice":0.7599,"preClose":0.7599,"latestTime":"19:38 EDT","volume":20,"amount":14.708,"timestamp":1744933130615},"delay":0,"floatShares":36127791,"shares":45483823,"eps":-2.153504,"marketStatus":"Closed Good Friday","change":0.0248,"latestTime":"04-17 16:00:00 EDT","open":0.729,"high":0.81,"low":0.729,"amount":39709.81967712,"amplitude":0.110189,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.153504,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1100235600000,"exchange":"NASDAQ","adjPreClose":0.7351,"preHourTrading":{"tag":"盘前","latestPrice":0.7895,"preClose":0.7351,"latestTime":"08:22 EDT","volume":280,"amount":216.37,"timestamp":1744892554090},"postHourTrading":{"tag":"盘后","latestPrice":0.7599,"preClose":0.7599,"latestTime":"19:38 EDT","volume":20,"amount":14.708,"timestamp":1744933130615},"volumeRatio":0.20958668859869595,"impliedVol":2.1502,"impliedVolPercentile":0.525},"requestUrl":"/m/hq/s/IRD","defaultTab":"news","newsList":[{"id":"2527457964","title":"PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath","url":"https://stock-news.laohu8.com/highlight/detail?id=2527457964","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527457964?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 22:36","pubTimestamp":1744727760,"startTime":"0","endTime":"0","summary":"Feature Details Company Milestones and 2025 Catalysts Across Gene Therapy and Ophthalmic Programs. NEW YORK, April 15, 2025  -- PRISM MarketView today published a Q&A feature with Dr. George Magrath, Chief Executive Officer of Opus Genetics, Inc.  , a clinical-stage gene therapy company developing treatments for inherited retinal diseases  and broader ophthalmic conditions.Dr. George Magrath, Chief Executive Officer of Opus Genetics, Inc.In the interview, Dr. Magrath outlines Opus Genetics’ recent milestones, including:. Completion of enrollment in two Phase 3 clinical trials: VEGA-3 for presbyopia and LYNX-2 for post-LASIK night vision disturbances;FDA Fast Track designation for phentolamine ophthalmic solution to treat chronic night driving impairment; and. Upcoming data presentations for OPGx-LCA5, an AAV-based gene therapy targeting Leber congenital amaurosis 5.The feature also explores Opus Genetics’ strategy to seek to build a repeatable gene therapy platform and anticipated clin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/prism-marketview-spotlights-opus-genetics-143600589.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LCA","BK4141","BK4007","IRD","MMAT"],"gpt_icon":0},{"id":"2526643881","title":"BRIEF-Mina Sooch Issues Open Letter To Opus Genetics' Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2526643881","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526643881?lang=en_us&edition=full_marsco","pubTime":"2025-04-12 03:53","pubTimestamp":1744401184,"startTime":"0","endTime":"0","summary":"BRIEF-Mina Sooch Issues Open Letter To Opus Genetics' StockholdersApril 11 (Reuters) - Mina Sooch:MINA SOOCH: ISSUED OPEN LETTER TO OPUS GENETICS' STOCKHOLDERSMINA SOOCH: TO EXERCISE RIGHTS AS A STOCK","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nFWN3QP1FB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2526648094","title":"Mina Sooch: to Exercise Rights as a Stockholder by Voting 'Withhold' on Opus Genetics Board’s Nominees in Proposal 1 at AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2526648094","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526648094?lang=en_us&edition=full_marsco","pubTime":"2025-04-12 03:48","pubTimestamp":1744400913,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nFWN3QP1FB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD"],"gpt_icon":0},{"id":"2526344358","title":"BRIEF-Opus Genetics says Mina Sooch Determined To Withdraw Her Slate Of Nominees For Election To Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2526344358","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526344358?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 05:45","pubTimestamp":1744235118,"startTime":"0","endTime":"0","summary":"BRIEF-Opus Genetics says Mina Sooch Determined To Withdraw Her Slate Of Nominees For Election To BoardApril 9  - Opus Genetics Inc IRD.O:MINA SOOCH - DETERMINED TO WITHDRAW HER SLATE OF NOMINEES FOR ELECTION TO OPUS GENETICS' BOARD AT THE ANNUAL MEETINGSource text: [ID:n0000921895-25-001042]Further company coverage: IRD.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN1YJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IRD"],"gpt_icon":0},{"id":"2526349362","title":"Mina Sooch - Determined to Withdraw Her Slate of Nominees for Election to Opus Genetics' Board at the Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2526349362","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526349362?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 05:08","pubTimestamp":1744232935,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN1YJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD"],"gpt_icon":0},{"id":"2525989673","title":"Opus Genetics Announces One-Month Clinical Data From Pediatric Patient in Phase 1/2 Trial of Opgx-Lca5 Gene Therapy in Inherited Retinal Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2525989673","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525989673?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 20:02","pubTimestamp":1744113753,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1HD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2525896753","title":"Opus Genetics- Second Pediatric Patient Recently Dosed, Pediatric Cohort Is Expected to Complete Enrollment in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2525896753","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525896753?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 20:02","pubTimestamp":1744113753,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1HD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD"],"gpt_icon":0},{"id":"2525896056","title":"Opus Genetics- First Pediatric Patient Shows Encouraging Early Safety Profile, Meaningful Improvement in Visual Function at One Month","url":"https://stock-news.laohu8.com/highlight/detail?id=2525896056","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525896056?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 20:02","pubTimestamp":1744113753,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1HD:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2525589605","title":"Opus Genetics Inc -Initial Data From All Three Patients Anticipated in Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2525589605","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525589605?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 20:02","pubTimestamp":1744113753,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1HD:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD"],"gpt_icon":0},{"id":"2525052896","title":"Opus Genetics Inc -Anticipates Pivotal Trial Could Initiate in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2525052896","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525052896?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 20:02","pubTimestamp":1744113753,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1HD:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2525993228","title":"Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2525993228","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525993228?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 20:00","pubTimestamp":1744113600,"startTime":"0","endTime":"0","summary":"First pediatric patient shows encouraging early safety profile and meaningful improvement in visual function at one month A second pediatric patient was recently dosed, and the pediatric cohort is exp","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057520/0/en/Opus-Genetics-Announces-One-Month-Clinical-Data-from-Pediatric-Patient-in-Phase-1-2-Trial-of-OPGx-LCA5-Gene-Therapy-in-Inherited-Retinal-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B1BXHZ80.USD","LCA","IE00BZ1G4Q59.USD","LU0170899867.USD","BK4023","SAP","BK4585","BK4006","LU1363072403.SGD","IE00BHPRN162.USD","KOL","LU0882574139.USD","LU0971096721.USD","BK4613","IE00BKVL7J92.USD","LU0267386448.USD","CMC","LU0149725797.USD","IRD","BK4007","BK4528"],"gpt_icon":0},{"id":"2525790765","title":"Party Time: Brokers Just Made Major Increases To Their Opus Genetics, Inc. (NASDAQ:IRD) Earnings Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=2525790765","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525790765?lang=en_us&edition=full_marsco","pubTime":"2025-04-05 20:42","pubTimestamp":1743856969,"startTime":"0","endTime":"0","summary":"Celebrations may be in order for Opus Genetics, Inc.  shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The analysts greatly increased their revenue estimates, suggesting a stark improvement in business fundamentals.Trump has pledged to \"unleash\" American oil and gas and these 15 US stocks have developments that are poised to benefit.Following the upgrade, the current consensus from Opus Genetics' three analysts is for revenues of US$17m in 2025 which - if met - would reflect a substantial 57% increase on its sales over the past 12 months. The loss per share is anticipated to greatly reduce in the near future, narrowing 37% to US$0.80. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$13m and losses of US$0.99 per share in 2025. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also redu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/party-time-brokers-just-made-124249859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","NDAQ","IRD"],"gpt_icon":1},{"id":"2525568367","title":"BRIEF-Opus Genetics Inc - Terminates Purchase Agreement With Lincoln Park - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2525568367","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525568367?lang=en_us&edition=full_marsco","pubTime":"2025-04-05 06:02","pubTimestamp":1743804160,"startTime":"0","endTime":"0","summary":"BRIEF-Opus Genetics Inc - Terminates Purchase Agreement With Lincoln Park - SEC FilingApril 4  - Opus Genetics Inc IRD.O:OPUS GENETICS INC - TERMINATES PURCHASE AGREEMENT WITH LINCOLN PARK - SEC FILINGSource text: [ID:n0001140361-25-012366]Further company coverage: IRD.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nFWN3QI20T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IRD"],"gpt_icon":0},{"id":"2525173008","title":"Opus Genetics Inc - Terminates Purchase Agreement With Lincoln Park - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2525173008","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525173008?lang=en_us&edition=full_marsco","pubTime":"2025-04-05 04:42","pubTimestamp":1743799330,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nFWN3QI20T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0},{"id":"2524460466","title":"Opus Genetics to Participate in Upcoming Investor Conference in April","url":"https://stock-news.laohu8.com/highlight/detail?id=2524460466","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524460466?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 20:00","pubTimestamp":1743595200,"startTime":"0","endTime":"0","summary":"RESEARCH TRIANGLE PARK, N.C., April 02, 2025  -- Opus Genetics, Inc. , a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases  and therapies for other ophthalmic disorders, today announced that George Magrath, M.D., Chief Executive Officer, will participate in the following upcoming investor conference in April.This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning data from our clinical trials.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opus-genetics-participate-upcoming-investor-120000365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LCA","BK4007","IRD"],"gpt_icon":0},{"id":"2524417641","title":"Opus Genetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2524417641","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524417641?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 19:42","pubTimestamp":1743594177,"startTime":"0","endTime":"0","summary":"Opus Genetics ( NASDAQ:IRD ) Full Year 2024 Results Key Financial Results Revenue: US$11.0m (down 42% from FY 2023...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ird/opus-genetics/news/opus-genetics-full-year-2024-earnings-revenues-beat-expectat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IRD"],"gpt_icon":0},{"id":"2524113022","title":"Opus Genetics Is Maintained at Buy by Jones Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2524113022","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524113022?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 20:33","pubTimestamp":1743510780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2025 08:33 ET (12:33 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD"],"gpt_icon":0},{"id":"2524197658","title":"Opus Genetics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2524197658","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524197658?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 19:37","pubTimestamp":1743507420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2025 07:37 ET (11:37 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD"],"gpt_icon":0},{"id":"2523946271","title":"Opus Genetics  FY24 EPS ($2.15) Down From ($0.46) YoY; Revenue $10.99M Down From $19.04M YoY.","url":"https://stock-news.laohu8.com/highlight/detail?id=2523946271","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523946271?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 20:28","pubTimestamp":1743424087,"startTime":"0","endTime":"0","summary":"Opus Genetics  FY24 EPS ($2.15) Down From ($0.46) YoY; Revenue $10.99M Down From $19.04M YoY.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44560064/opus-genetics-fy24-eps-2-15-down-from-0-46-yoy-revenue-10-99m-down-from-19-04m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD"],"gpt_icon":0},{"id":"2523946607","title":"Opus Genetics Announces Financial Results for Full Year 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2523946607","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523946607?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 20:20","pubTimestamp":1743423626,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUA5WN38T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocuphire.com","stockEarnings":[{"period":"1week","weight":0.0646},{"period":"1month","weight":-0.3154},{"period":"3month","weight":-0.3275},{"period":"6month","weight":-0.4243},{"period":"1year","weight":-0.5633},{"period":"ytd","weight":-0.3614}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.074201},{"month":2,"riseRate":0.47619,"avgChangeRate":0.057078},{"month":3,"riseRate":0.333333,"avgChangeRate":0.005763},{"month":4,"riseRate":0.4,"avgChangeRate":0.507546},{"month":5,"riseRate":0.6,"avgChangeRate":4.57464},{"month":6,"riseRate":0.4,"avgChangeRate":-0.017062},{"month":7,"riseRate":0.35,"avgChangeRate":-0.003257},{"month":8,"riseRate":0.35,"avgChangeRate":-0.024514},{"month":9,"riseRate":0.45,"avgChangeRate":-0.02299},{"month":10,"riseRate":0.25,"avgChangeRate":-0.106096},{"month":11,"riseRate":0.3,"avgChangeRate":-0.065242},{"month":12,"riseRate":0.47619,"avgChangeRate":0.059596}],"exchange":"NASDAQ","name":"OPUS GENETICS INC","nameEN":"OPUS GENETICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OPUS GENETICS INC(IRD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OPUS GENETICS INC(IRD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OPUS GENETICS INC,IRD,OPUS GENETICS INC股票,OPUS GENETICS INC股票老虎,OPUS GENETICS INC股票老虎国际,OPUS GENETICS INC行情,OPUS GENETICS INC股票行情,OPUS GENETICS INC股价,OPUS GENETICS INC股市,OPUS GENETICS INC股票价格,OPUS GENETICS INC股票交易,OPUS GENETICS INC股票购买,OPUS GENETICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OPUS GENETICS INC(IRD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OPUS GENETICS INC(IRD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction